{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:45:02Z","timestamp":1791233102231,"version":"4.1.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T00:00:00Z","timestamp":1427155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/nrurol.2015.58","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T04:24:07Z","timestamp":1427171047000},"page":"225-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":166,"title":["Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Barton","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Uchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,24]]},"reference":[{"key":"BFnrurol201558_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bju.12012","volume":"112","author":"JA Witjes","year":"2013","unstructured":"Witjes, J. A. et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 112, 742\u2013750 (2013).","journal-title":"BJU Int."},{"issue":"Suppl. 5","key":"BFnrurol201558_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/184291a0","volume":"184","author":"LJ Old","year":"1959","unstructured":"Old, L. J., Clarke, D. A. & Benacerraf, B. Effect of Bacillus Calmette-Gu\u00e9rin infection on transplanted tumours in the mouse. Nature 184 (Suppl. 5), 291\u2013292 (1959).","journal-title":"Nature"},{"key":"BFnrurol201558_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales, A., Eidinger, D. & Bruce, A. W. Intracavitary Bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors. J. Urol. 116, 180\u2013183 (1976).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm, D. L. et al. Bacillus Calmette-Gu\u00e9rin immunotherapy of superficial bladder cancer. J. Urol. 124, 38\u201340 (1980).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR5","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314\u20132330 (2007).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64, 639\u2013653 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","volume":"11","author":"PE Clark","year":"2013","unstructured":"Clark, P. E. et al. Bladder cancer. J. Natl Compr. Canc. Netw. 11, 446\u2013475 (2013).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrurol201558_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.eursup.2008.07.009","volume":"7","author":"D Lamm","year":"2008","unstructured":"Lamm, D. et al. Clinical practice recommendations for the management of non\u2013muscle invasive bladder cancer. Eur. Urol. Suppl. 7, 651\u2013666 (2008).","journal-title":"Eur. Urol. Suppl."},{"key":"BFnrurol201558_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 36\u201344 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester, R. J. et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol. 57, 766\u2013773 (2010).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat, A. M. et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J. Urol. 192, 305\u2013315 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm, D. L. et al. Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124\u20131129 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","volume":"112","author":"NM Gandhi","year":"2013","unstructured":"Gandhi, N. M., Morales, A. & Lamm, D. L. Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer. BJU Int. 112, 288\u2013297 (2013).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"RA Badalament","year":"1987","unstructured":"Badalament, R. A. et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer. J. Clin. Oncol. 5, 441\u2013449 (1987).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","volume":"138","author":"MA Hudson","year":"1987","unstructured":"Hudson, M. A. et al. Single course versus maintenance bacillus Calmette-Gu\u00e9rin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol. 138, 295\u2013298 (1987).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza, H., Hinotsu, S., Aso, Y., Kakizoe, T. & Koiso, K. Bacillus Calmette-Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75, 552\u2013559 (1995).","journal-title":"Cancer"},{"key":"BFnrurol201558_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","volume":"165","author":"J Palou","year":"2001","unstructured":"Palou, J. et al. Control group and maintenance treatment with bacillus Calmette-Gu\u00e9rin for carcinoma in situ and\/or high grade bladder tumors. J. Urol. 165, 1488\u20131491 (2001).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","volume":"17","author":"H Koga","year":"2010","unstructured":"Koga, H. et al. Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int. J. Urol. 17, 759\u2013766 (2010).","journal-title":"Int. J. Urol."},{"key":"BFnrurol201558_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","volume":"108","author":"S Hinotsu","year":"2011","unstructured":"Hinotsu, S. et al. Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 108, 187\u2013195 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","volume":"57","author":"M Duchek","year":"2010","unstructured":"Duchek, M. et al. Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-\u03b12b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur. Urol. 57, 25\u201331 (2010).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JOP.2011.000480","volume":"9","author":"BA Spencer","year":"2013","unstructured":"Spencer, B. A. et al. Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J. Oncol. Pract. 9, 92\u201398 (2013).","journal-title":"J. Oncol. Pract."},{"key":"BFnrurol201558_CR22","unstructured":"Merck Sharp & Dohme B.V. TICE\u00ae BCG LIVE (for intravesical use) - Prescribing Information [online] , (2013)."},{"key":"BFnrurol201558_CR23","first-page":"18","volume":"44","author":"AB Bloch","year":"1995","unstructured":"Bloch, A. B. Screeening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm. Rep. 44, 18\u201334 (1995).","journal-title":"MMWR Recomm. Rep."},{"key":"BFnrurol201558_CR24","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot, C. et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci. Transl. Med. 4, 137ra72 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrurol201558_CR25","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","volume":"169","author":"CY Bilen","year":"2003","unstructured":"Bilen, C. Y., Inci, K., Erkan, I. & Ozen, H. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Gu\u00e9rin. J. Urol. 169, 1702\u20131705 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2490-9-10","volume":"9","author":"EM Gaughan","year":"2009","unstructured":"Gaughan, E. M. et al. HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management. BMC Urol. 9, 10 (2009).","journal-title":"BMC Urol."},{"key":"BFnrurol201558_CR27","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","volume":"175","author":"FN Joudi","year":"2006","unstructured":"Joudi, F. N., Smith, B. J., O'Donnell, M. A. & Konety, B. R. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J. Urol. 175, 1634\u20131639; discussion 1639\u20131640 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR28","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1056\/NEJMc062714","volume":"355","author":"P Hoffmann","year":"2006","unstructured":"Hoffmann, P., Roumegu\u00e8re, T., Schulman, C. & van Velthoven, R. Use of statins and outcome of BCG treatment for bladder cancer. N. Engl. J. Med. 355, 2705\u20132707 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol201558_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1056\/NEJMc070117","volume":"356","author":"AM Kamat","year":"2007","unstructured":"Kamat, A. M. & Wu, X. Statins and the effect of BCG on bladder cancer. N. Engl. J. Med. 356, 1276; author reply 1276\u20131277 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol201558_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.juro.2008.06.034","volume":"180","author":"RK Berglund","year":"2008","unstructured":"Berglund, R. K., Savage, C. J., Vora, K. C., Kurta, J. M. & Cronin, A. M. An analysis of the effect of statin use on the efficacy of bacillus Calmette-Gu\u00e9rin treatment for transitional cell carcinoma of the bladder. J. Urol. 180, 1297\u20131300; discussion 1300 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR31","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1111\/bju.12150","volume":"112","author":"JJ Crivelli","year":"2013","unstructured":"Crivelli, J. J. et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int. 112, E4\u2013E12 (2013).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1464-410X.2008.08123.x","volume":"103","author":"JR Gee","year":"2009","unstructured":"Gee, J. R. et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Gu\u00e9rin. BJU Int. 103, 736\u2013739 (2009).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR33","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.juro.2010.06.149","volume":"184","author":"HM Rosevear","year":"2010","unstructured":"Rosevear, H. M., Lightfoot, A. J., Nepple, K. G. & O'Donnell, M. A. Safety and efficacy of intravesical bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. J. Urol. 184, 1920\u20131924 (2010).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR34","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1161\/CIRCULATIONAHA.106.183095","volume":"116","author":"W Wilson","year":"2007","unstructured":"Wilson, W. et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116, 1736\u20131754 (2007).","journal-title":"Circulation"},{"key":"BFnrurol201558_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","volume":"1","author":"DL Lamm","year":"1995","unstructured":"Lamm, D. L. et al. Randomized intergroup comparison of bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a Southwest Oncology Group study. Urol. Oncol. 1, 119\u2013126 (1995).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201558_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel, M. et al. The effect of ofloxacin on bacillus Calmette-Gu\u00e9rin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J. Urol. 176, 935\u2013939 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","volume":"104","author":"R Damiano","year":"2009","unstructured":"Damiano, R. et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity? BJU Int. 104, 633\u2013639 (2009).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR38","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens, J. et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 63, 462\u2013472 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1586\/era.09.35","volume":"9","author":"FM Martin","year":"2009","unstructured":"Martin, F. M. & Kamat, A. M. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev. Anticancer Ther. 9, 815\u2013820 (2009).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"BFnrurol201558_CR40","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr, H. W. & Dalbagni, G. Defining bacillus Calmette-Gu\u00e9rin refractory superficial bladder tumors. J. Urol. 169, 1706\u20131708 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","volume":"24","author":"MA O'Donnell","year":"2006","unstructured":"O'Donnell, M. A. & Boehle, A. Treatment options for BCG failures. World J. Urol. 24, 481\u2013487 (2006).","journal-title":"World J. Urol."},{"key":"BFnrurol201558_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1464-410X.1995.tb07307.x","volume":"75","author":"VW Merz","year":"1995","unstructured":"Merz, V. W. et al. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Gu\u00e9rin for carcinoma in situ of the bladder. Br. J. Urol. 75, 180\u2013184 (1995).","journal-title":"Br. J. Urol."},{"key":"BFnrurol201558_CR43","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","volume":"187","author":"AM Kamat","year":"2012","unstructured":"Kamat, A. M. et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Gu\u00e9rin therapy for bladder cancer: results of a prospective trial. J. Urol. 187, 862\u2013867 (2012).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR44","volume-title":"2013 Genitourinary Cancers Symposium Daily News","author":"DL Willis","year":"2013","unstructured":"Willis, D. L. & Kamat, A. M. Clinical trials examining BCG treatment failure: improving trial design, options in intravesical therapy. 2013 Genitourinary Cancers Symposium Daily News [online] , (2013)."},{"key":"BFnrurol201558_CR45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","volume":"178","author":"Y Fradet","year":"2007","unstructured":"Fradet, Y. et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J. Urol. 178, 68\u201373; discussion 73 (2007).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1309\/6396QUBU6HEJBMPL","volume":"126","author":"K Glatz","year":"2006","unstructured":"Glatz, K. et al. An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system. Am. J. Clin. Pathol. 126, 294\u2013301 (2006).","journal-title":"Am. J. Clin. Pathol."},{"key":"BFnrurol201558_CR47","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"GN Thalmann","year":"2000","unstructured":"Thalmann, G. N. et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Gu\u00e9rin. J. Urol. 164, 2129\u20132133 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ijc.11352","volume":"107","author":"F Saint","year":"2003","unstructured":"Saint, F. et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy. Int. J. Cancer 107, 434\u2013440 (2003).","journal-title":"Int. J. Cancer"},{"key":"BFnrurol201558_CR49","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","volume":"14","author":"R Kaempfer","year":"1996","unstructured":"Kaempfer, R. et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol. 14, 1778\u20131786 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR50","unstructured":"Kamat, A. M., Briggman, J., Dinney, C. P. & Urbauer, D. The use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer. WO\/2013\/131093 (2013)."},{"key":"BFnrurol201558_CR51","doi-asserted-by":"publisher","first-page":"e38533","DOI":"10.1371\/journal.pone.0038533","volume":"7","author":"H Wei","year":"2012","unstructured":"Wei, H. et al. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Gu\u00e9rin. PLoS ONE 7, e38533 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrurol201558_CR52","doi-asserted-by":"publisher","unstructured":"Lima, L. et al. The role of functional polymorphisms in immune response genes as biomarkers of BCG immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int. http:\/\/dx.doi.org\/10.1111\/bju.12844 .","DOI":"10.1111\/bju.12844"},{"key":"BFnrurol201558_CR53","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","volume":"16","author":"YJ Kim","year":"2010","unstructured":"Kim, Y. J. et al. Gene signatures for the prediction of response to Bacillus Calmette-Gu\u00e9rin immunotherapy in primary pT1 bladder cancers. Clin. Cancer Res. 16, 2131\u20132137 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201558_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"BFnrurol201558_CR55","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1100\/tsw.2011.30","volume":"11","author":"AJ Lightfoot","year":"2011","unstructured":"Lightfoot, A. J., Rosevear, H. M. & O'Donnell, M. A. Recognition and treatment of BCG failure in bladder cancer. ScientificWorldJournal 11, 602\u2013613 (2011).","journal-title":"ScientificWorldJournal"},{"key":"BFnrurol201558_CR56","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg, G. et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Gu\u00e9rin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 163, 761\u2013767 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MOU.0b013e328356ac0a","volume":"22","author":"T Lebret","year":"2012","unstructured":"Lebret, T. & Neuzillet, Y. Indication and timing of cystectomy in high-risk bladder cancer. Curr. Opin. Urol. 22, 427\u2013431 (2012).","journal-title":"Curr. Opin. Urol."},{"issue":"Suppl. 4","key":"BFnrurol201558_CR58","first-page":"S188","volume":"3","author":"KG Nepple","year":"2009","unstructured":"Nepple, K. G. & O'Donnell, M. A. The optimal management of T1 high-grade bladder cancer. Can. Urol. Assoc. J. 3 (Suppl. 4), S188\u2013S192 (2009).","journal-title":"Can. Urol. Assoc. J."},{"key":"BFnrurol201558_CR59","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U","volume":"85","author":"L Cheng","year":"1999","unstructured":"Cheng, L. et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85, 2469\u20132474 (1999).","journal-title":"Cancer"},{"key":"BFnrurol201558_CR60","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","volume":"164","author":"F Mill\u00e1n-Rodr\u00edguez","year":"2000","unstructured":"Mill\u00e1n-Rodr\u00edguez, F. et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol. 164, 680\u2013684 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR61","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr, H. W. & Sogani, P. C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 166, 1296\u20131299 (2001).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"WJ Catalona","year":"1987","unstructured":"Catalona, W. J., Hudson, M. A., Gillen, D. P., Andriole, G. L. & Ratliff, T. L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Gu\u00e9rin therapy for superficial bladder cancer. J. Urol. 137, 220\u2013224 (1987).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR63","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000090870","volume":"76","author":"M Gacci","year":"2006","unstructured":"Gacci, M. et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol. Int. 76, 106\u2013111 (2006).","journal-title":"Urol. Int."},{"key":"BFnrurol201558_CR64","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Y Luo","year":"1999","unstructured":"Luo, Y., Chen, X., Downs, T. M., DeWolf, W. C. & O'Donnell, M. A. IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Gu\u00e9rin immunotherapy. J. Immunol. 162, 2399\u20132405 (1999).","journal-title":"J. Immunol."},{"key":"BFnrurol201558_CR65","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1084\/jem.190.8.1155","volume":"190","author":"NA Fanger","year":"1999","unstructured":"Fanger, N. A., Maliszewski, C. R., Schooley, K. & Griffith, T. S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190, 1155\u20131164 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnrurol201558_CR66","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","volume":"159","author":"AS Belldegrun","year":"1998","unstructured":"Belldegrun, A. S. et al. Superficial bladder cancer: the role of interferon-\u03b1. J. Urol. 159, 1793\u20131801 (1998).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR67","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","volume":"172","author":"MA O'Donnell","year":"2004","unstructured":"O'Donnell, M. A., Lilli, K., Leopold, C. & National Bacillus Calmette-Gu\u00e9rin\/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2b for superficial bladder cancer. J. Urol. 172, 888\u2013893 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR68","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0090-4295(01)01187-6","volume":"58","author":"LG Luciani","year":"2001","unstructured":"Luciani, L. G., Neulander, E., Murphy, W. M. & Wajsman, Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 58, 376\u2013379 (2001).","journal-title":"Urology"},{"key":"BFnrurol201558_CR69","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","volume":"21","author":"JS Lam","year":"2003","unstructured":"Lam, J. S. et al. Bacillus Calmete-Gu\u00e9rin plus interferon-\u03b12B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol. Oncol. 21, 354\u2013360 (2003).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201558_CR70","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi, F. N., Smith, B. J., O'Donnell, M. A. & National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol. 24, 344\u2013348 (2006).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201558_CR71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1179\/joc.2002.14.2.194","volume":"14","author":"NK Mohanty","year":"2002","unstructured":"Mohanty, N. K., Malhotra, V., Nayak, R. L. & Arora, R. P. Combined low-dose intravesical immunotherapy (BCG + interferon \u03b1-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother. 14, 194\u2013197 (2002).","journal-title":"J. Chemother."},{"key":"BFnrurol201558_CR72","doi-asserted-by":"publisher","first-page":"35.e21","DOI":"10.1016\/j.urolonc.2013.02.010","volume":"32","author":"D Lamm","year":"2014","unstructured":"Lamm, D., Brausi, M., O'Donnell, M. A. & Witjes, J. A. Interferon \u03b1 in the treatment paradigm for non-muscle-invasive bladder cancer. Urol. Oncol. 32, 35.e21\u201335.e30 (2014).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201558_CR73","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"KG Nepple","year":"2010","unstructured":"Nepple, K. G. et al. Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J. Urol. 184, 1915\u20131919 (2010).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR74","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","volume":"163","author":"MA O'Donnell","year":"1999","unstructured":"O'Donnell, M. A. et al. Role of IL-12 in the induction and potentiation of IFN-\u03b3 in response to bacillus Calmette-Gu\u00e9rin. J. Immunol. 163, 4246\u20134252 (1999).","journal-title":"J. Immunol."},{"key":"BFnrurol201558_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","volume":"164","author":"E Kaasinen","year":"2000","unstructured":"Kaasinen, E. et al. Weekly mitomycin C followed by monthly bacillus Calmette-Gu\u00e9rin or alternating monthly interferon-\u03b12B and bacillus Calmette-Gu\u00e9rin for prophylaxis of recurrent papillary superficial bladder carcinoma. J. Urol. 164, 47\u201352 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR76","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2011","unstructured":"Colombo, R., Salonia, A., Leib, Z., Pavone-Macaluso, M. & Engelstein, D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 107, 912\u2013918 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi, S. M. et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7, 43\u201351 (2006).","journal-title":"Lancet Oncol."},{"key":"BFnrurol201558_CR78","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","volume":"59","author":"W Oosterlinck","year":"2011","unstructured":"Oosterlinck, W. et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Gu\u00e9rin and with bacillus Calmette-Gu\u00e9rin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur. Urol. 59, 438\u2013446 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR79","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1464-410X.2012.11390.x","volume":"111","author":"BB Houghton","year":"2013","unstructured":"Houghton, B. B. et al. Intravesical chemotherapy plus bacille Calmette-Gu\u00e9rin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int. 111, 977\u2013983 (2013).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR80","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0022-5347(17)36577-1","volume":"148","author":"C Bouffioux","year":"1992","unstructured":"Bouffioux, C. et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J. Urol. 148, 297\u2013301 (1992).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR81","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"R Bartoletti","year":"2005","unstructured":"Bartoletti, R. et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 66, 726\u2013731 (2005).","journal-title":"Urology"},{"key":"BFnrurol201558_CR82","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo, R. et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol. 28, 543\u2013548 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR83","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni, G. et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Gu\u00e9rin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24, 2729\u20132734 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR84","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","volume":"190","author":"EC Skinner","year":"2013","unstructured":"Skinner, E. C. et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin. J. Urol. 190, 1200\u20131204 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR85","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","volume":"189","author":"LJ Barlow","year":"2013","unstructured":"Barlow, L. J., McKiernan, J. M. & Benson, M. C. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy. J. Urol. 189, 834\u2013839 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR86","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1442-2042.2001.00355.x","volume":"8","author":"H Sekine","year":"2001","unstructured":"Sekine, H., Ohya, K., Kojima, S. I., Igarashi, K. & Fukui, I. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Gu\u00e9rin therapy for carcinoma in situ of the bladder. Int. J. Urol. 8, 483\u2013486 (2001).","journal-title":"Int. J. Urol."},{"key":"BFnrurol201558_CR87","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","volume":"190","author":"P Gontero","year":"2013","unstructured":"Gontero, P. et al. The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J. Urol. 190, 857\u2013862 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR88","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","volume":"24","author":"JM McKiernan","year":"2006","unstructured":"McKiernan, J. M. et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol. 24, 3075\u20133080 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR89","doi-asserted-by":"publisher","first-page":"35.e15","DOI":"10.1016\/j.urolonc.2013.01.009","volume":"32","author":"AJ Lightfoot","year":"2014","unstructured":"Lightfoot, A. J. et al. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol. Oncol. 32, 35.e15\u201335.e19 (2014).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201558_CR90","unstructured":"Steinberg, R. L. et al. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer (in press)."},{"key":"BFnrurol201558_CR91","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","volume":"88","author":"PJ Gray","year":"2014","unstructured":"Gray, P. J. et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int. J. Radiat. Oncol. Biol. Phys. 88, 1048\u20131056 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrurol201558_CR92","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","volume":"63","author":"PJ Gray","year":"2013","unstructured":"Gray, P. J. et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur. Urol. 63, 823\u2013829 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201558_CR93","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1464-410X.1986.tb09015.x","volume":"58","author":"PM Quilty","year":"1986","unstructured":"Quilty, P. M. & Duncan, W. Treatment of superficial (T1) tumours of the bladder by radical radiotherapy. Br. J. Urol. 58, 147\u2013152 (1986).","journal-title":"Br. J. Urol."},{"key":"BFnrurol201558_CR94","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0936-6555(05)80838-6","volume":"3","author":"MK Gospodarowicz","year":"1991","unstructured":"Gospodarowicz, M. K. et al. Bladder cancer: long-term follow-up results of patients treated with radical radiation. Clin. Oncol. (R. Coll. Radiol.) 3, 155\u2013161 (1991).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrurol201558_CR95","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.juro.2007.05.024","volume":"178","author":"SJ Harland","year":"2007","unstructured":"Harland, S. J. et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J. Urol. 178, 807\u2013813; discussion 813 (2007).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR96","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","volume":"24","author":"C Weiss","year":"2006","unstructured":"Weiss, C. et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol. 24, 2318\u20132324 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR97","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1464-410X.2008.08299.x","volume":"104","author":"JY Wo","year":"2009","unstructured":"Wo, J. Y. et al. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int. 104, 179\u2013183 (2009).","journal-title":"BJU Int."},{"key":"BFnrurol201558_CR98","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Bladder Cancer Version 1.2015 [online] , (2015)."},{"key":"BFnrurol201558_CR99","unstructured":"Radiation Therapy Oncology Group. RTOG 0926 Protocol Information [online] , (2014)."},{"key":"BFnrurol201558_CR100","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.urolonc.2010.07.001","volume":"30","author":"SY Ping","year":"2012","unstructured":"Ping, S. Y., Wu, C. L. & Yu, D. S. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway. Urol. Oncol. 30, 652\u2013659 (2012).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201558_CR101","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/CAD.0b013e32832ced78","volume":"20","author":"DJ Chen","year":"2009","unstructured":"Chen, D. J. & Huerta, S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 20, 646\u2013658 (2009).","journal-title":"Anticancer Drugs"},{"key":"BFnrurol201558_CR102","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-03-1327","volume":"106","author":"TJ Kemp","year":"2005","unstructured":"Kemp, T. J. et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) results in the release of functional soluble TRAIL\/Apo-2L. Blood 106, 3474\u20133482 (2005).","journal-title":"Blood"},{"key":"BFnrurol201558_CR103","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig, A. T. et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Gu\u00e9rin-induced antitumor activity. Cancer Res. 64, 3386\u20133390 (2004).","journal-title":"Cancer Res."},{"key":"BFnrurol201558_CR104","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1189\/jlb.1211623","volume":"92","author":"GG Jinesh","year":"2012","unstructured":"Jinesh, G. G., Chunduru, S. & Kamat, A. M. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-\u03b1 but not through TRAIL and FasL. J. Leukoc. Biol. 92, 233\u2013244 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrurol201558_CR105","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/S0022-5347(17)35272-2","volume":"151","author":"Y Mizutani","year":"1994","unstructured":"Mizutani, Y., Nio, Y., Fukumoto, M. & Yoshida, O. Enhanced antitumor effect of Bacillus Calmette-Gu\u00e9rin in combination with fibrinogen on urinary bladder tumor. J. Urol. 151, 1420\u20131426 (1994).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR106","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman, B. A. et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109, 1499\u20131505 (2007).","journal-title":"Cancer"},{"key":"BFnrurol201558_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2014)."},{"key":"BFnrurol201558_CR108","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke, J. M. et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 2391\u20132397 (2012).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR109","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CP Dinney","year":"2013","unstructured":"Dinney, C. P. et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J. Urol. 190, 850\u2013856 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR110","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","volume":"61","author":"AP Berger","year":"2003","unstructured":"Berger, A. P. et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61, 338\u2013341 (2003).","journal-title":"Urology"},{"key":"BFnrurol201558_CR111","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1089\/089277903322518644","volume":"17","author":"MJ Manyak","year":"2003","unstructured":"Manyak, M. J. & Ogan, K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J. Endourol. 17, 633\u2013639 (2003).","journal-title":"J. Endourol."},{"key":"BFnrurol201558_CR112","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","volume":"190","author":"JY Lee","year":"2013","unstructured":"Lee, J. Y. et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Gu\u00e9rin immunotherapy. J. Urol. 190, 1192\u20131199 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR113","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"E Olsen","year":"2001","unstructured":"Olsen, E. et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376\u2013388 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201558_CR114","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","volume":"188","author":"M Kowalski","year":"2012","unstructured":"Kowalski, M. et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Gu\u00e9rin. J. Urol. 188, 1712\u20131718 (2012).","journal-title":"J. Urol."},{"key":"BFnrurol201558_CR115","first-page":"1957","volume":"7","author":"NH Chow","year":"2001","unstructured":"Chow, N. H., Chan, S. H., Tzai, T. S., Ho, C. L. & Liu, H. S. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7, 1957\u20131962 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201558_CR116","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/1078-0432.CCR-12-1258","volume":"19","author":"X Yang","year":"2013","unstructured":"Yang, X. et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin. Cancer Res. 19, 148\u2013157 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201558_CR117","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1166\/jbn.2014.1838","volume":"10","author":"SK Cho","year":"2014","unstructured":"Cho, S. K. et al. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J. Biomed. Nanotechnol. 10, 1267\u20131276 (2014).","journal-title":"J. Biomed. Nanotechnol."},{"key":"BFnrurol201558_CR118","first-page":"5915","volume":"7","author":"A Szlachcic","year":"2012","unstructured":"Szlachcic, A. et al. FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int. J. Nanomedicine 7, 5915\u20135927 (2012).","journal-title":"Int. J. Nanomedicine"},{"key":"BFnrurol201558_CR119","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cas.12075","volume":"104","author":"K Kawai","year":"2013","unstructured":"Kawai, K., Miyazaki, J., Joraku, A., Nishiyama, H. & Akaza, H. Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 104, 22\u201327 (2013).","journal-title":"Cancer Sci."},{"key":"BFnrurol201558_CR120","doi-asserted-by":"publisher","unstructured":"Morales, A. et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin. J. Urol. http:\/\/dx.doi.org\/10.1016\/j.juro.2014.09.109 .","DOI":"10.1016\/j.juro.2014.09.109"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2015.58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2015.58","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2015.58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T19:41:01Z","timestamp":1691523661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2015.58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,24]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFnrurol201558"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2015.58","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,24]]},"assertion":[{"value":"24 March 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}